



Modern Slavery Statement 2025

Lilly

About Lilly

Lilly is a medicine company making life better for people around the world. We've turned science into pioneering new discoveries for 150 years, and today, our medicines support more than 58 million people across the globe.

Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges. Redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing options for some of the most debilitating immune system disorders; and targeting the most difficult-to-treat cancers.

With each step towards a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.



Our Purpose and Values

Lilly unites caring with discovery to create medicines that make life better for people around the world. We aim to grow and operate our business in a responsible, sustainable way and are committed to creating a safe, supportive, ethical, and rewarding work environment. Lilly's three core values guide us in all that we do:

Integrity

We conduct our business consistently with all applicable laws. We are honest in our interactions with patients, customers, and employees.

Excellence

We pursue pharmaceutical innovation, provide high-quality products and strive to deliver superior business results.

Respect for people

We maintain an environment built on mutual respect, openness and individual integrity. We're committed to the wellbeing of all people who touch or are touched by our company: patients, customers, health care professionals, employees, shareholders, and communities. Lilly supports the United Nations Global Compact Ten Principles on respecting internationally proclaimed human rights.

While our purpose encapsulates discovering innovative medicines, it also guides our commitment to ensure employees, partners and suppliers uphold our values and respect human rights as we work together to improve lives.



Our Local organisation

Lilly Australia and New Zealand (Lilly ANZ) are part of the Eli Lilly Group of Companies (“Lilly”). Our ultimate parent company, Eli Lilly and Company, is located in Indianapolis, United States. Lilly researches, develops, manufactures, and sells pharmaceutical products around the world. Lilly ANZ promotes and sells Lilly products in Australia and New Zealand (NZ) and facilitates the conduct of local clinical trials for the company.

Lilly ANZ’s suppliers provide goods and services across a range of categories, including sales, marketing and administration, distribution and warehousing arrangements, clinical trials, real-world evidence research, and information technology. In the reporting period, Lilly ANZ predominantly contracted suppliers in Australia and New Zealand. It sourced limited goods and services from suppliers located in other countries.

Support including procurement and the engagement of suppliers is provided to New Zealand by Lilly Australia. Certain directors of Lilly Australia are also the directors of Lilly NZ and have a full understanding of Lilly NZ’s business operations and supply chain.



Addressing Risk of Modern Slavery

This statement describes the actions taken by Eli Lilly Australia Pty Ltd ("Lilly Australia") to assess and address the risks of modern slavery in its operations and supply chain, and in those of its wholly controlled entity, Eli Lilly and Company New Zealand Limited ("Lilly NZ"), together referred to as Lilly ANZ. It was prepared by Lilly Australia, the reporting entity, pursuant to section 13 of the Modern Slavery Act 2018 (Cth) for the annual accounting period ending 31 December 2025.

In the consultation process, members of the local leadership team and the key functions supporting the two reporting entities, including Procurement, Supply Chain, Ethics & Compliance and Legal were engaged. This involved knowledge sharing on current practices and compliance activities between employees from the Australian reporting entities and other relevant stakeholders within the broader Lilly corporate group such as the UK and US affiliates.

Lilly supports the United Nations Global Compact principles, adheres to human rights and labour laws, and complies with anti-corruption practices. In 2011, Lilly revised its global standards and procedures to include specific language about human rights, including Lilly's expectation that suppliers abide by human rights standards as part of the Lilly Supplier Code of Business Conduct.

Lilly is an active participant in the Pharmaceutical Supply Chain Initiative ("PSCI") industry group and adopted the PSCI principles for responsible supply chain management in 2009. The PSCI principles are designed to align with the principles of the United Nations Global Compact. They represent high-level expectations set for industry suppliers in the areas of ethics, labour, health and safety, the environment and related management systems. Lilly's Supplier Code of Business Conduct reflects the PSCI principles.

Our Annual Risk Assessment

We have continued to include modern slavery risk in our local risk assessment process for the engagement of suppliers engaged by Lilly.

This assessment must be completed prior to engaging new suppliers and when renewing engagements with existing suppliers. All suppliers assessed to have a high-risk of likelihood of modern slavery (that is, on both risk dimensions: country of supplier and category of goods or services) are subject to increased scrutiny and additional due diligence, which can include site visits and inspections.

Further, if a supplier is assessed as high risk, procurement and legal departments must be consulted prior to progressing with an engagement. If a supplier is assessed as high risk on one rating only (that is, country or category of services/goods), they are flagged for further assessment and investigation.



Overview of the Assessment

Lilly Australia monitors recommendations for compliance with regulations addressing modern slavery throughout the year. We liaise with other Lilly affiliates with similar requirements to share best practices across countries. Locally, we have continued to complete an annual review of Lilly ANZ’s supplier base to include an assessment of modern slavery risks, adopting the methodology used in our initial assessment and as reported below.

Lilly Australia has used the Global Slavery Index (GSI) report to assess the risk of its vendors in previous years. Utilising the updated 2023 GSI report, risk was assessed based on country and category of goods or services, being the most determinative factors in assessing the likelihood of modern slavery risk.

For the purpose of assessing the risk of modern slavery for the reporting period, Lilly ANZ conducted a risk assessment of its Tier 1 suppliers (that is, suppliers from which Lilly ANZ directly procures goods and services). Tier 1 suppliers continue to be considered the appropriate base for assessment. Tier 1 suppliers were characterised as:

- All vendors listed in finance systems from which Lilly ANZ procured goods or services in the reporting period, totaling 806 suppliers.
- Suppliers that Lilly ANZ procured goods and services from in the reporting period, excluding categories outlined below totaling 236 suppliers.
- Some categories of Tier 1 suppliers were excluded from the assessment, including healthcare professionals, charitable organisations, clinical trial investigators, clinical trials research organisations, government institutions, healthcare organisations, patient organisations and expenses charged to corporate credit cards.

236	806	9	0
Suppliers Assessed	All Suppliers	Suppliers in High-Risk Countries	High-Risk Suppliers

For the purposes of the assessment, high-risk countries were considered those in the top 133 of 180 countries, that is above 0.25% estimated prevalence of modern slavery per 1,000 population.

Most Tier 1 suppliers were assessed as low-risk, as both country and category were low-risk. There were no Tier 1 suppliers in both a high-risk country and a high-risk category, and consequently, no Tier 1 suppliers were categorised as high-risk.



The breakdown of Tier 1 suppliers by country of origin is set out in the table below:

Country / Region	Number of Suppliers	Geography High Risk Category	GSI Risk Category	Outcome
Australia	203	No	Low	Low Risk
New Zealand	17	No	Low	Low Risk
United Kingdom	7	No	Low	Low Risk
USA	7	Yes	Low	Low Risk
Hong Kong	1	Yes	Low	Low Risk
India	1	Yes	Low	Low Risk
Total	236			0 High-Risk

Most suppliers are located in low-risk countries, with nine exceptions – one in Hong Kong, one in India and seven in the USA. There were 220 of 236 Tier 1 suppliers based in Australia and New Zealand and seven in the United Kingdom, all countries considered low-risk.

The relevant services provided by the nine suppliers in Hong Kong, India and the USA are low-risk and Lilly will consider appropriate action if there is a change in scope of services that will put these suppliers in a high-risk category.

Reducing the Risk of Modern Slavery in our Operations and Supply Chain

Our Culture of Integrity and Ethical Behaviour

Lilly is committed to upholding high standards of corporate conduct in our business dealings. The Red Book, our policies and procedures, compliance management systems, training programs and communications are designed to work together to reinforce a culture of integrity and ethical behaviour. Lilly's strong compliance culture is supported by its Ethics and Compliance, Human Resources, Legal, Finance and Procurement, Quality and Audit Departments. Lilly is committed to improving our positive impact in Environmental, Social & Governance areas. Lilly develops goals at corporate level and monitors its performance on these areas annually.

Internal Accountability

Our employees, globally, must comply with The Red Book, our internal code of business conduct. The Red Book is a statement of principles that guides Lilly's operations. These principles are based on 11 corporate policies and are consistent with our company values of integrity, excellence, and respect for people. The Red Book sets the expectation for behaviour and provides the ethical framework of the business. Lilly's global procedures, standards and training align with the Red Book. Our whistle blower protection policy, 'Speaking Up: No Retaliation', encourages all employees to report known or suspected issues, concerns, or behaviour that could harm Lilly or its stakeholders. Our policies reinforce our culture of upholding the highest standards and conduct in all business activities.

Training

Lilly requires all employees, including supply chain management, to complete ongoing training and education on The Red Book, associated policies and procedures, and applicable legal requirements for specific roles. Under Lilly global and ANZ procedures, all employees must follow ethical procurement practices and procurement must be engaged in all transactions over a certain material spend. Employees across various functions receive targeted training and education in order to work with third-parties.

Ensuring the Effectiveness of these Actions

We recognise that modern slavery is a complex issue that can manifest at different levels in a supply chain. As we continue to exercise due diligence, monitoring activities and further engagement with suppliers, we will assess the effectiveness of the actions we take and consider measures that may be additionally required to uncover modern slavery risk.



Compliance Review and Contracting

In compliance with Lilly global procedures, suppliers in Lilly ANZ's supply chain are reviewed for relevant compliance and quality issues at the initiation of their relationship with Lilly ANZ. This includes an assessment of modern slavery risk. All agreements require that suppliers represent and warrant to Lilly ANZ that they comply with all applicable laws and regulations, as well as Lilly's Supplier Code of Business Conduct.

Agreements

Based on the nature and level of the risk identified, in addition to incorporating the Lilly Supplier Code of Business Conduct, Legal may incorporate additional terms including audit rights, or otherwise tailor the terms of the agreement to address the risk identified. Lilly ANZ reserves the right to terminate the agreement of any suppliers that do not meet the expectations under its contractual arrangements.

Additional Assessment of Modern Slavery Risk

If a vendor is identified as high-risk, we require the supplier to perform a self-assessment questionnaire (SAQ). If risk factors are identified, risk mitigation action and remediation plans must be developed and progressed by the supplier – prior to Lilly ANZ proceeding with the engagement. No SAQs were performed in this reporting period.

Awareness and Education

The Lilly ANZ Leadership Team continues its commitment to ensuring we understand and address modern slavery risks in our Lilly ANZ operations and supply chain. We continue to educate and train Lilly ANZ leadership and relevant employees on modern slavery risk, appropriate decision-making, swift reporting and action. Modern slavery awareness training is included in our internal procurement training process for relevant stakeholders. Through this we reinforce the importance of assessing modern slavery risks in our operations, and Lilly ANZ's requirements when engaging suppliers.



Acting with Integrity and Respect for People.

Through Lilly's focus on supporting human rights and making a meaningful contribution to the world, we will continue to identify and address the risk of modern slavery in our business operations. Refer to [Lilly's 2024 Sustainability Report](#) and [ESG Strategy](#) for more information about our work.

This statement was approved by the Board of Directors of Eli Lilly Australia Pty Ltd on 23 June 2026. For further information please contact Katherine Burchfield, Director, Policy & Public Affairs at katherine.burchfield@lilly.com.



Manny Simons

General Manager & Director, Eli Lilly Australia Pty Ltd ACN 000 233 992

23 June 2026

